Seed Thomas, Kumar Sree, Whitnall Mark, Srinivasan Venkataraman, Singh Vijay, Elliott Thomas, Landauer Michael, Miller Alexandra, Chang Cheng-Min, Inal Cyndi, Deen Jason, Gehlhaus Martin, Jackson William, Hilyard Edward, Pendergrass James, Toles Raymond, Villa Vilmar, Miner Venita, Stewart Michael, Benjack James, Danilenko Dimitry, Farrell Ckatherine
Radiation Casualty Management, Armed Forces Radiobiology Research Institute, Bethesda, MD 20889-5603, USA.
J Radiat Res. 2002 Dec;43 Suppl:S239-44. doi: 10.1269/jrr.43.s239.
New strategies for the prevention of radiation injuries are currently being explored with the ultimate aim of developing globally radioprotective, nontoxic pharmacologics. The prophylactic treatments under review encompass such diverse pharmacologic classes as novel immunomodulators, nutritional antioxidants, and cytokines. An immunomodulator that shows promise is 5-androstenediol (AED), a well-tolerated, long-acting androstene steroid with broad-spectrum radioprotective attributes that include not only protection against acute tissue injury, but also reduced susceptibility to infectious agents, as well as reduced rates of neoplastic transformation. Other potentially useful radioprotectants currently under study include the nutraceutical vitamin E and analogs, a chemically-engineered cytokine, interleukin-1beta, and a sustained-release formulation of an aminothiol, amifostine. Results suggest that a new paradigm is evolving for the prophylaxes of radiation injuries, based on use of newly identified, nontoxic, broad-spectrum prophylactic agents whose protective action may be leveraged by subsequent postexposure use of cytokines with organ-specific reparative functions.